Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to permit the patients with schizophrenia who received Sertindole during a previous randomised trial, study 99824, to continue with this treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: H. Lundbeck A/S
• Treatments: Sertindole

Criteria

Inclusion Criteria:

• Participation in the previous SCoP study, 99824

• Still fulfils the EU SPC requirements for Sertindole

Exclusion Criteria:

• Withdrawn before the end of the SCoP study, 99824

• Become homeless

• Participation in another clinical trial at the same time

• Unlikely to comply with the clinical study protocol or is unsuitable for any reason